Jose Maria Gonzalez-de-Echavarri
Overview
Explore the profile of Jose Maria Gonzalez-de-Echavarri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
367
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Flores A, Garcia-Tornel A, Sero L, Ustrell X, Requena M, Pellise A, et al.
J Neurointerv Surg
. 2023 Apr;
16(2):143-150.
PMID: 37068936
Background: The influence of vascular imaging acquisition on workflows at local stroke centers (LSCs) not capable of performing thrombectomy in patients with a suspected large vessel occlusion (LVO) stroke remains...
2.
Akinci M, Sanchez-Benavides G, Brugulat-Serrat A, Pena-Gomez C, Palpatzis E, Shekari M, et al.
Alzheimers Res Ther
. 2022 Sep;
14(1):126.
PMID: 36068641
Background: The COVID-19 pandemic may worsen the mental health of people reporting subjective cognitive decline (SCD) and therefore their clinical prognosis. We aimed to investigate the association between the intensity...
3.
Brugulat-Serrat A, Canas-Martinez A, Canals-Gispert L, Marne P, Gramunt N, Mila-Aloma M, et al.
J Alzheimers Dis
. 2021 Sep;
84(1):119-128.
PMID: 34569957
Background: Cognitive performance of a given individual should be interpreted in the context of reference standards obtained in cognitively healthy populations. Recent evidence has shown that removing asymptomatic individuals with...
4.
Mila-Aloma M, Brinkmalm A, Ashton N, Kvartsberg H, Shekari M, Operto G, et al.
Neurology
. 2021 Sep;
97(21):e2065-e2078.
PMID: 34556565
Background And Objectives: To determine whether CSF synaptic biomarkers are altered in the early preclinical stage of the Alzheimer continuum and associated with Alzheimer disease (AD) risk factors, primary pathology,...
5.
Aracil-Bolanos I, Sampedro F, Marin-Lahoz J, Horta-Barba A, Martinez-Horta S, Gonzalez-de-Echavarri J, et al.
Brain Imaging Behav
. 2021 Sep;
16(2):761-772.
PMID: 34553331
Mild cognitive impairment in Parkinson's disease (PD-MCI) is associated with consistent structural and functional brain changes. Whether different approaches for diagnosing PD-MCI are equivalent in their neural correlates is presently...
6.
Aracil-Bolanos I, Sampedro F, Pujol J, Soriano-Mas C, Gonzalez-de-Echavarri J, Kulisevsky J, et al.
Hum Brain Mapp
. 2021 Sep;
42(17):5736-5746.
PMID: 34510640
Dopamine-replacing therapies are an effective treatment for the motor aspects of Parkinson's disease. However, its precise effect over the cognitive resting-state networks is not clear; whether dopaminergic treatment normalizes their...
7.
Mila-Aloma M, Shekari M, Salvado G, Gispert J, Arenaza-Urquijo E, Operto G, et al.
Alzheimers Res Ther
. 2021 Jul;
13(1):134.
PMID: 34315519
Background: Understanding the changes that occur in the transitional stage between absent and overt amyloid-β (Aβ) pathology within the Alzheimer's continuum is crucial to develop therapeutic and preventive strategies. The...
8.
Vilor-Tejedor N, Evans T, Adams H, Gonzalez-de-Echavarri J, Molinuevo J, Guigo R, et al.
Neurol Genet
. 2021 Jun;
7(3):e591.
PMID: 34124350
There is clear evidence that hippocampal subfield volumes have partly distinct genetic determinants associated with specific biological processes. The identification of genetic correlates of hippocampal subfield volumes may help to...
9.
Sanchez-Benavides G, Suarez-Calvet M, Mila-Aloma M, Arenaza-Urquijo E, Grau-Rivera O, Operto G, et al.
Neurobiol Aging
. 2021 May;
104:24-31.
PMID: 33962331
Neurofilament light chain (NfL) is an axonal protein that when measured in cerebrospinal fluid (CSF) serves as a biomarker of neurodegeneration. We aimed at investigating the association among CSF NfL,...
10.
Grau-Rivera O, Navalpotro-Gomez I, Sanchez-Benavides G, Suarez-Calvet M, Mila-Aloma M, Arenaza-Urquijo E, et al.
Alzheimers Res Ther
. 2021 Feb;
13(1):46.
PMID: 33597012
Background: Recognizing clinical manifestations heralding the development of Alzheimer's disease (AD)-related cognitive impairment could improve the identification of individuals at higher risk of AD who may benefit from potential prevention...